Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

• Forschungsstelle: INNOSUISSE
• Projektnummer: 40713.1 IP-LS
• Projekttitel Englisch: Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

Kurzbeschreibung (Deutsch)

Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

Kurzbeschreibung (Englisch)

Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

Abstract (Deutsch)

PharmaBiome is pioneering the development of next-generation microbiome therapies. To bridge the gap from proof of concept to the clinic we will validate the worldwide first co-cultivated microbiome product in relevant animal models of colitis as part of the preclinical studies.

Abstract (Englisch)